Premium
Molecular testing in metastatic colorectal adenocarcinoma cytology cell pellets
Author(s) -
McHugh Kelsey E.,
Dermawan Josephine K.,
Cheng YuWei,
Cruise Michael,
Sohal Davendra P. S.,
Reynolds Jordan P.
Publication year - 2019
Publication title -
diagnostic cytopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.417
H-Index - 65
eISSN - 1097-0339
pISSN - 8755-1039
DOI - 10.1002/dc.24275
Subject(s) - kras , neuroblastoma ras viral oncogene homolog , medicine , cytopathology , cytology , colorectal cancer , adenocarcinoma , oncology , pathology , cancer , cancer research
Background Mutational status for KRAS , NRAS , and BRAF genes should be performed on all colorectal carcinoma (CRC) specimens in order to guide targeted therapy selection for metastatic disease. Mutations are typically assessed via polymerase chain reaction and/or next generation sequencing (NGS) on formalin‐fixed paraffin‐embedded tissues. With minimally invasive diagnostic methodologies, the cytology cell pellet obtained by fine‐needle aspiration (FNA) can serve as an alternative source of tumor deoxyribonucleic acid. Methods An electronic record review of the cytopathology files (CoPathPlus, Cerner Corp., North Kansas City, Missouri) from September 1, 2015 through December 31, 2018 was conducted. All cytology specimens obtained via FNA and diagnosed as metastatic CRC on which NGS was performed were included. NGS for KRAS , NRAS , and BRAF mutations using the AmpliSeq Cancer Hotspot Panel v2.0 kit (Thermo Fisher Scientific, Waltham, Massachusetts) was performed on cytology cell pellets. Results Forty‐eight cases were identified. Forty‐six of 48 specimens (96%) were adequate for molecular testing. Of those adequate specimens, proportion of malignant cells in the sample ranged from 5% to 95% (mean 46%). Twenty‐seven of 48 cases (56%) were positive for clinically relevant mutations. Twenty‐four of 27 cases (89%) were positive for KRAS mutations, with exon 2 most frequently involved (22/24 cases, 92%). Two of 27 cases (7%) were positive for NRAS mutations and one case (1/27, 4%) was positive for a BRAF mutation involving codon 594. Conclusion Mutational analysis performed on cytology cell pellets serves as a useful means of gathering clinically actionable information on tumor mutation status in metastatic CRC.